BioTuesdays

Maxim reduces PTs in challenging biotech market

Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...

Pliant Therapeutics

Cantor starts Pliant Therapeutics at OW; PT $12

Cantor Fitzgerald launched coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.93 on May 24. Pliant is developing novel therapies for...

Cantor starts Lyra Therapeutics at OW; PT $15

Cantor Fitzgerald initiated coverage of Lyra Therapeutics (NASDAQ:LYRA) with an “overweight” rating and price target of $15. The stock closed at $6.07 on May 23. Lyra is a clinical-stage company developing medicines...

HilleVax

Analysts start HilleVax at buy, outperform

Analysts for Stifel and SVB Securities initiated coverage of HilleVax (NASDAQ:HLVX) with “buy” and “outperform” ratings, and price targets of $34 and $30, respectively. The stock closed at $9.50 on May 23. The company’s...

Humacyte

Piper cuts Humacyte to underweight; PT to $4 from $10

Piper Sandler downgraded Humacyte (NASDAQ:HUMA) to “underweight” from “overweight” and reduced its price target to $4 from $10, citing the sizable stock pullback in the sector. The stock closed at $5.37 on May 13. The...

89bio

BTIG slashes 89bio PT to $28 from $60

BTIG reduced its price target for 89bio (NASDAQ:ETNB) to $28 from $60 but maintained its “buy” rating after making model updates and increasing its modeled discount rate to 14% from 12%. The stock closed at $2.67 on May...

Pulse Biosciences Logo

HCW cuts Pulse Biosciences to neutral; withdraws PT

H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” without a price target, reflecting a lack of clarity about Pulse’s commercial timelines and funding availability. The stock closed at $1...

BTIG halves Poseida Therapeutics PT to $20 from $40

BTIG slashed its price target for Poseida Therapeutics (NASDAQ:PSTX) to $20 from $40 but maintained its “buy” rating after increasing its modeled discount rate to 14% from $12, given current market conditions. The stock...

Athira Pharma

BTIG starts Athira Pharma at buy; PT $33

BTIG launched coverage of Athira Pharma (NASDAQ:ATHA) with a “buy” rating and $33 price target. The stock closed at $8.84 on May 9. Athira is developing fosgonimeton for the treatment of Alzheimer’s disease, pervasive...

Maxim starts Oncternal at buy; PT $3.50

Maxim Group initiated coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and price target of $3.50. The stock closed at 99 cents on May 9. Oncternal is a clinical-stage company focused on novel targets...

180-Life-Sciences

Maxim cuts 180 Life Sciences to hold; withdraws PT

Maxim Group downgraded 180 Life Sciences (NASDAQ:ATNF) to “hold” from “buy” and withdrew its price target, citing a financing overhang. The stock closed at $1.31 on May 6. Several weeks ago, 180 announced the...

Amarin

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

Aligos-Therapeutics

SVB cuts Aligos to market perform; PT to $3 from $7

SVB Securities downgraded Aligos Therapeutics (NASDAQ:ALGS) to “market perform” from “outperform” and slashed its price target to $3, which is close to cash, from $7, citing a slow catalyst path ahead with a legal...

Shattuck Labs

HCW starts Shattuck Labs at buy; PT $28

H.C. Wainwright initiated coverage of Shattuck Labs (NASDAQ:STTK) with a “buy” rating and price target of $28. The stock closed at $3.84 on April 29. To overcome the shortcomings of current immunomodulatory cancer...

Vera-Therapeutics

HCW starts Vera Therapeutics at buy; PT $35

H.C. Wainwright launched coverage of Vera Therapeutics (NASDAQ:VERA) with a “buy” rating and $35 price target. The stock closed at $20 on April 29. Vera is a clinical-stage biotech company focused on developing disease...

acutus logo

BTIG ups Acutus Medical to buy; PT $2

BTIG upgraded Acutus Medical (NASDAQ:AFIB) to “buy” from “neutral” with a price target of $2, after the company announced a debt refinancing and the sale of its left-heart access product portfolio that should extend its...

Opthea-Logo

SVB starts Opthea at OP; PT $25

SVB Securities launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $25 price target. The stock closed at $5.71 on April 25. Opthea is a clinical-stage biotechnology company focused on developing...

Maxim starts Processa Pharma at buy; PT $9

Maxim Group initiated coverage of Processa Pharmaceuticals (NASDAQ:PCSA) with a “buy” rating and $9 price target. The stock closed at $2.87 on April 18. Processa is a clinical-stage company developing therapies for...

AN2 Theraputics

SVB Leerink starts AN2 Therapeutics at OP; PT $27

SVB Leerink launched coverage of AN2 Therapeutics (NASDAQ:ANTX) with an “outperform” rating and price target of $27. The stock closed at $14.79 on April 18.   AN2 is a clinical-stage biotech company developing therapies...

Biodesix Logo

BTIG ups Biodesix PT to $17 from $10

BTIG raised its price target for Biodesix (NASDAQ:BDSX) to $17 from $10, saying “performance this year should restore investor confidence.” The stock closed at $1.61 on April 14. Analyst Sung Ji Nam writes that the...